Rule 3.19A.2
Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.
Introduced 30/09/01 Amended 01/01/11
Name of entity CYCLOPHARM LIMITED
ABN 74 116 931 250
We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.
Name of Director | James McBrayer |
Date of last notice | 28/6/2016 |
Part 1 ‐ Change of director's relevant interests in securities
In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust
Note: In the case of a company, interests which come within paragraph (i) of the definition of "notifiable interest of a director" should be disclosed in this part.
Direct or indirect interest | Direct |
Nature of indirect interest (including registered holder) Note: Provide details of the circumstances giving rise to the relevant interest. | N/A |
Date of change | 30/6/2017 |
No. of securities held prior to change | 3,536,828 held by
|
Class | Ordinary Shares |
Number acquired | 13,502 |
Number disposed | Nil |
Value/Consideration Note: If consideration is non‐cash, provide details and estimated valuation | $10,801.60 |
+ See chapter 19 for defined terms.
01/01/2011 Appendix 3Y Page 1
Appendix 3Y Change of Director's Interest NoticeNo. of securities held after change | 3,550,330 held by
|
Nature of change Example: on‐market trade, off‐market trade, exercise of options, issue of securities under dividend reinvestment plan, participation in buy‐back | Issue of shares under non‐renounceable entitlement offer |
Note: In the case of a company, interests which come within paragraph (ii) of the definition of "notifiable interest of a director" should be disclosed in this part.
Detail of contract | Nil |
Nature of interest | Nil |
Name of registered holder (if issued securities) | Nil |
Date of change | Nil |
No. and class of securities to which interest related prior to change Note: Details are only required for a contract in relation to which the interest has changed | Nil |
Interest acquired | Nil |
Interest disposed | Nil |
Value/Consideration Note: If consideration is non‐cash, provide details and an estimated valuation | Nil |
Interest after change | Nil |
Were the interests in the securities or contracts detailed above traded during a +closed period where prior written clearance was required? | No |
If so, was prior written clearance provided to allow the trade to proceed during this period? | Not Applicable |
If prior written clearance was provided, on what date was this provided? | Not Applicable |
+ See chapter 19 for defined terms.
Appendix 3Y Page 2 01/01/2011
Cyclopharm Limited published this content on 04 July 2017 and is solely responsible for the information contained herein.
Distributed by Public, unedited and unaltered, on 06 July 2017 08:45:11 UTC.
Original documenthttp://cyc.live.irmau.com/irm/PDF/1514_0/ChangeofDirector39sInterestNoticeJMcBrayer
Public permalinkhttp://www.publicnow.com/view/A5095569BC27E873E1FCF35E50F649FDFF11FDB8